bioAffinity Technologies Unveils New CyPath® Lung Case Study

bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update.

On September 9, 2025, bioAffinity Technologies announced a new case study demonstrating the effectiveness of its CyPath® Lung test in identifying lung cancer in a patient with ground-glass nodules. The test shifted the patient’s care from a prolonged period of watchful waiting to immediate treatment, highlighting its potential to improve patient outcomes by providing timely, actionable information. This advancement underscores the product’s capability to reduce uncertainty in diagnosing difficult-to-assess lung nodules, positioning bioAffinity Technologies as a key player in enhancing lung cancer diagnostics.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The overall stock score reflects significant financial challenges and bearish technical indicators, which are partially offset by positive corporate events. The company’s weak financial performance and valuation are the most significant factors impacting the score.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on developing noninvasive diagnostics for lung cancer and other lung diseases. Their flagship product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. The company aims to address the need for early-stage cancer diagnosis and broad-spectrum cancer treatments.

Average Trading Volume: 4,440,187

Technical Sentiment Signal: Sell

Current Market Cap: $6.8M

Find detailed analytics on BIAF stock on TipRanks’ Stock Analysis page.